•  
  •  
  •  
  •  

2026-07-22 09:12:44

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  FinalApproval

Stock Report

  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Fingolimod Capsules, 0.5 mg
  • Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg
  • Caplin Steriles gets USFDA approval for Desmopressin Acetate Injection
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Efinaconazole Topical Solution, 10%
  • Caplin Steriles gets USFDA approval for Sodium Phosphates Injection
  • Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
  • Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025